2009; Enginler et al. 2014), and ESR1 (Borge et al. 2013) with CMT risk. Drawing from known BC susceptibility and general DNA repair/maintenance genes, a host of potential CMT genes‐ BRIP, CDH1, ERBB2 (also called HER2), PTEN, STK11 and TP53‐ are suspected (Borge et al. 2011), but confirmatory case–control experiments have not been conducted. This assumption provides a springboard for CMT‐variant discovery, but should not limit future and more unbiased BC/CMT gene discovery investigation (Chandler et al. 2016). This evidence concerns the gene CDH1 and breast cancer.